AbbVie has received a positive opinion from the Committee for Medicinal Products for Human Use for its ribavirin-free regimen Maviret for the treatment of chronic hepatitis C of all genotypes, according to a press release.

“Maviret represents a new generation of HCV therapy and has the potential to be a shorter, 8-week option for patients living with this serious, chronic illness,” Michael Severino, MD, executive vice president, research and development and chief scientific officer at AbbVie, said in the release. “Today’s CHMP positive opinion takes us closer to delivering on AbbVie’s mission to address continued unmet needs by bringing a new pan-genotypic option to people living with HCV in Europe.”